Guard Therapeutics International AB Sustainability Reports
A clinical-stage biotechnology company that identifies and develops new therapies for diseases with large unmet medical needs, focusing on various forms of kidney disease. Its candidate drugs are primarily based on the endogenous protein alpha-1-microglobulin.
Sector: Manufacturing
Country: Sweden
Exchange: Nasdaq Stockholm
LEI: 549300DTX7T87FGYG180
1 reports from 2020 to 2020
